FDA slaps a hold on a star Regeneron cancer drug, pausing trial enrollment as cytokine storms trigger new tox tempest
Less than two years after one of Regeneron’s star cancer drugs was in the spotlight following the death of two patients from cytokine storms, odronextamab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
